{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:46:21Z","timestamp":1794257181402,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ARIS Slovenian Research and Innovation Agency research and infrastructure program","award":["P3-0308"],"award-info":[{"award-number":["P3-0308"]}]},{"name":"ARIS Slovenian Research and Innovation Agency research and infrastructure program","award":["P3-0308"],"award-info":[{"award-number":["P3-0308"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Psoriasis is a chronic, immune-mediated disease. The systemic inflammation triggered by psoriasis contributes significantly to increased cardiovascular risk. While various treatments completely clear the skin, the associated effects on systemic inflammation are not yet clear. We investigated residual systemic inflammation in successfully treated patients. Circulating disease-specific and non-specific inflammatory markers were measured and compared in 80 psoriasis patients (aged 30\u201345\u00a0years) successfully treated with topical therapy, methotrexate, adalimumab, secukinumab or guselkumab, and in 20 healthy controls. Non-specific inflammatory markers (high-sensitivity C-reactive protein\u00a0(hs-CRP), complete blood count (CBC)\u00a0parameters, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume-to-platelet ratio (MPR), and red blood\u00a0cell distribution width-to-platelet ratio (RPR)) and disease-specific inflammatory markers (interferon-\u03b3 (IFN-\u03b3), tumor necrosis factor (TNF), interleukin\u00a0(IL)-1\u03b2, IL-12p70, IL-17, and IL-23) were measured and compared between groups. Disease-specific cytokines (IFN-\u03b3, TNF, IL-1\u03b2, IL-12p70, and IL-17, but not IL-23), were significantly elevated in patients compared to controls, while non-specific inflammatory markers showed no differences compared to controls. The residual disease-specific cytokines were similarly elevated in all five treated groups. In addition, they correlated significantly with body mass index (BMI) and waist circumference. Our results suggest that psoriasis patients have elevated residual disease-specific cytokines despite successful treatment, while the non-specific inflammatory markers are similar to those in control subjects. Residual disease-specific inflammatory markers correlated with BMI and waist circumference. A possible beneficial effect of body weight control in psoriasis patients merits further investigation. The study was registered at\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\" ext-link-type=\"uri\">http:\/\/clinicaltrials.gov<\/jats:ext-link>\n                    (identifier: NCT05957120) on July 24, 2023.\n                  <\/jats:p>","DOI":"10.1007\/s12026-024-09584-4","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T10:13:27Z","timestamp":1736331207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Residual non-specific and disease-specific inflammatory markers in successfully treated young psoriasis patients: a cross-sectional study"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1634-1868","authenticated-orcid":false,"given":"Eva Klara","family":"Merzel \u0160abovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0415-5160","authenticated-orcid":false,"given":"Tadeja","family":"Kraner \u0160umenjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-6353","authenticated-orcid":false,"given":"Mojca","family":"Bo\u017ei\u010d Mijovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7073-8922","authenticated-orcid":false,"given":"Miodrag","family":"Jani\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"9584_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/1346-8138.15913","volume":"48","author":"K Yamanaka","year":"2021","unstructured":"Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: a review. J Dermatol. 2021;48:722\u201331. https:\/\/doi.org\/10.1111\/1346-8138.15913.","journal-title":"J Dermatol"},{"key":"9584_CR2","doi-asserted-by":"publisher","first-page":"12793","DOI":"10.3390\/ijms222312793","volume":"22","author":"R Singh","year":"2021","unstructured":"Singh R, Koppu S, Perche PO, Feldman SR. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021;22:12793. https:\/\/doi.org\/10.3390\/ijms222312793.","journal-title":"Int J Mol Sci"},{"key":"9584_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jdv.18044","volume":"36","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36:797\u2013806. https:\/\/doi.org\/10.1111\/jdv.18044.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9584_CR4","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.3390\/ijms23126648","volume":"23","author":"EK Merzel \u0160abovi\u0107","year":"2022","unstructured":"Merzel \u0160abovi\u0107 EK, Starbek Zorko M, Jani\u0107 M. Killing two birds with one stone: potential therapies targeting psoriasis and atherosclerosis at the same time. Int J Mol Sci. 2022;23:6648. https:\/\/doi.org\/10.3390\/ijms23126648.","journal-title":"Int J Mol Sci."},{"key":"9584_CR5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, M\u00e4lk\u00f6nen T, Maul JT, Mburu S, Mrowietz U, Reich K, Remenyik E, R\u00f8nholt KM, Sator PG, Schmitt-Egenolf M, Sikora M, Str\u00f6mer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris \u2013 part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34:2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9584_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/BTT.S252578","volume":"15","author":"N Brownstone","year":"2021","unstructured":"Brownstone N, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, Koo J. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021;15:39\u201351. https:\/\/doi.org\/10.2147\/BTT.S252578.","journal-title":"Biologics"},{"key":"9584_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/bjd.12355","volume":"169","author":"EA Dowlatshahi","year":"2013","unstructured":"Dowlatshahi EA, van der Voort EAM, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169:266\u201382. https:\/\/doi.org\/10.1111\/bjd.12355.","journal-title":"Br J Dermatol"},{"key":"9584_CR8","doi-asserted-by":"publisher","unstructured":"Grechin C, Solov\u0103stru L, V\u25a1\u021b\u0103 D, P\u0103tra\u0219cu A, Gr\u0103jdeanu A, Porumb-Andrese E. Inflammatory marker alteration in response to systemic therapies in psoriasis. Exp Ther Med. 2020. https:\/\/doi.org\/10.3892\/etm.2020.8535.","DOI":"10.3892\/etm.2020.8535"},{"key":"9584_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.02.013","author":"Q Li","year":"2024","unstructured":"Li Q, Pang B, Dang E, Wang G. Endothelial dysfunction in psoriasis: an integrative review. J Investig Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jid.2024.02.013.","journal-title":"J Investig Dermatol"},{"key":"9584_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/1346-8138.15278","volume":"47","author":"A Morita","year":"2020","unstructured":"Morita A, Tani Y, Matsumoto K, Yamaguchi M, Teshima R, Ohtsuki M. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab. J Dermatol. 2020;47:452\u20137. https:\/\/doi.org\/10.1111\/1346-8138.15278.","journal-title":"J Dermatol"},{"key":"9584_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/09629350310001619753","volume":"12","author":"SE Jacob","year":"2003","unstructured":"Jacob SE, Nassiri M, Kerdel FA, Vincek V. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm. 2003;12:309\u201313. https:\/\/doi.org\/10.1080\/09629350310001619753.","journal-title":"Mediators Inflamm"},{"key":"9584_CR12","doi-asserted-by":"publisher","unstructured":"Wang Y, Zang J, Liu C, Yan Z, Shi D. Interleukin-17 links inflammatory cross-talks between comorbid psoriasis and atherosclerosis. Front Immunol 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.835671.","DOI":"10.3389\/fimmu.2022.835671"},{"key":"9584_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2230.2009.03704.x","volume":"35","author":"H Takahashi","year":"2009","unstructured":"Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol. 2009;35:645\u20139. https:\/\/doi.org\/10.1111\/j.1365-2230.2009.03704.x.","journal-title":"Clin Exp Dermatol"},{"key":"9584_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/819149","volume":"2015","author":"PSS de Oliveira","year":"2015","unstructured":"de Oliveira PSS, Cardoso PRG, de Lima EVA, Pereira MC, Duarte ALBP, da Pitta IR, de R\u00eago MJBM, da Pitta MGR. IL-17A, IL-22, IL-6, and IL-21 serum levels in plaque-type psoriasis in Brazilian patients. Mediators Inflamm. 2015;2015:1\u20135. https:\/\/doi.org\/10.1155\/2015\/819149.","journal-title":"Mediators Inflamm"},{"key":"9584_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1155\/2013\/856056","volume":"35","author":"A Michalak-Stoma","year":"2013","unstructured":"Michalak-Stoma A, Bartosi\u0144ska J, Kowal M, Juszkiewicz-Borowiec M, Gerkowicz A, Chodorowska G. Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis Markers. 2013;35:625\u201331. https:\/\/doi.org\/10.1155\/2013\/856056.","journal-title":"Dis Markers"},{"key":"9584_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.18632\/oncotarget.22260","volume":"9","author":"F Bai","year":"2018","unstructured":"Bai F, Zheng W, Dong Y, Wang J, Garstka MA, Li R, An J, Ma H. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2018;9:1266\u201378. https:\/\/doi.org\/10.18632\/oncotarget.22260.","journal-title":"Oncotarget"},{"key":"9584_CR17","doi-asserted-by":"publisher","first-page":"e0293327","DOI":"10.1371\/journal.pone.0293327","volume":"18","author":"X-Q Liu","year":"2023","unstructured":"Liu X-Q, Zhou P-L, Yin X-Y, Wang A-X, Wang D-H, Yang Y, Liu Q. Circulating inflammatory cytokines and psoriasis risk: a systematic review and meta-analysis. PLoS ONE. 2023;18:e0293327. https:\/\/doi.org\/10.1371\/journal.pone.0293327.","journal-title":"PLoS ONE"},{"key":"9584_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2787954","volume":"2022","author":"D Hong","year":"2022","unstructured":"Hong D, Liu X, Qiu X, Lu S, Jiang Y, Tan G, Shi Z, Wang L. Profiling serum cytokines and anticytokine antibodies in psoriasis patients. J Immunol Res. 2022;2022:1\u20139. https:\/\/doi.org\/10.1155\/2022\/2787954.","journal-title":"J Immunol Res"},{"key":"9584_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00403-012-1229-1","volume":"304","author":"SB Yilmaz","year":"2012","unstructured":"Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304:465\u20139. https:\/\/doi.org\/10.1007\/s00403-012-1229-1.","journal-title":"Arch Dermatol Res"},{"key":"9584_CR20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","volume":"139","author":"F Kolbinger","year":"2017","unstructured":"Kolbinger F, Loesche C, Valentin M-A, Jiang X, Cheng Y, Jarvis P, Peters T, Calonder C, Bruin G, Polus F, Aigner B, Lee DM, Bodenlenz M, Sinner F, Pieber TR, Patel DD. \u03b2-Defensin 2 is a responsive biomarker of IL-17A\u2013driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017;139:923-932.e8. https:\/\/doi.org\/10.1016\/j.jaci.2016.06.038.","journal-title":"J Allergy Clin Immunol"},{"key":"9584_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/MI.2005.273","volume":"2005","author":"O Arican","year":"2005","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-\u03b1, IFN-\u03b3, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005:273\u20139. https:\/\/doi.org\/10.1155\/MI.2005.273.","journal-title":"Mediators Inflamm"},{"key":"9584_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/467541","volume":"2014","author":"A Kyriakou","year":"2014","unstructured":"Kyriakou A, Patsatsi A, Vyzantiadis T-A, Sotiriadis D. Serum levels of TNF- \u03b1, IL-12\/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity. J Immunol Res. 2014;2014:1\u20139. https:\/\/doi.org\/10.1155\/2014\/467541.","journal-title":"J Immunol Res"},{"key":"9584_CR23","doi-asserted-by":"publisher","unstructured":"de Alcantara CC, Reiche EMV, Sim\u00e3o ANC. Cytokines in psoriasis. 2021;171\u2013204. https:\/\/doi.org\/10.1016\/bs.acc.2020.04.004.","DOI":"10.1016\/bs.acc.2020.04.004"},{"key":"9584_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/joim.12002","volume":"273","author":"K-H Yiu","year":"2013","unstructured":"Yiu K-H, Yeung C-K, Zhao C-T, Chan JC, Siu C-W, Tam S, Wong C-S, Yan GH, Yue WS, Khong P-L, Chan HH, Tse H-F. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med. 2013;273:273\u201382. https:\/\/doi.org\/10.1111\/joim.12002.","journal-title":"J Intern Med"},{"key":"9584_CR25","doi-asserted-by":"publisher","unstructured":"Niknezhad N, Haghighatkhah HR, Zargari O, Ghalamkarpour F, Younespour S, Niknejad N, Alikhan A, Abdollahimajd F. High\u2010sensitivity C\u2010reactive protein as a biomarker in detecting subclinical atherosclerosis in psoriasis. Dermatol Ther 2020;33. https:\/\/doi.org\/10.1111\/dth.13628.","DOI":"10.1111\/dth.13628"},{"key":"9584_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bjd.20963","volume":"186","author":"L Puig","year":"2022","unstructured":"Puig L, Costanzo A, Mu\u00f1oz-El\u00edas EJ, Jazra M, Wegner S, Paul CF, Conrad C. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. Br J Dermatol. 2022;186:773\u201381. https:\/\/doi.org\/10.1111\/bjd.20963.","journal-title":"Br J Dermatol"},{"key":"9584_CR27","doi-asserted-by":"publisher","first-page":"100116","DOI":"10.1016\/j.xjidi.2022.100116","volume":"2","author":"D Tian","year":"2022","unstructured":"Tian D, Lai Y. The relapse of psoriasis: mechanisms and mysteries. JID Innov. 2022;2:100116. https:\/\/doi.org\/10.1016\/j.xjidi.2022.100116.","journal-title":"JID Innov"},{"key":"9584_CR28","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.3390\/ijms24076390","volume":"24","author":"K Kie\u0142bowski","year":"2023","unstructured":"Kie\u0142bowski K, Bakinowska E, Ostrowski P, Pala B, Gromowska E, Gurazda K, Dec P, Modrzejewski A, Pawlik A. The role of adipokines in the pathogenesis of psoriasis. Int J Mol Sci. 2023;24:6390. https:\/\/doi.org\/10.3390\/ijms24076390.","journal-title":"Int J Mol Sci"},{"key":"9584_CR29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/0003319719845186","volume":"70","author":"A Kurtul","year":"2019","unstructured":"Kurtul A, Ornek E. Platelet to lymphocyte ratio in cardiovascular diseases: a systematic review. Angiology. 2019;70:802\u201318. https:\/\/doi.org\/10.1177\/0003319719845186.","journal-title":"Angiology"},{"key":"9584_CR30","doi-asserted-by":"publisher","unstructured":"Kvist\u2010Hansen A, Kaiser H, Krakauer M, G\u00f8rtz PM, Wang X, Becker C, Zachariae C, Hansen PR, Skov L. Neutrophil\u2010to\u2010lymphocyte ratio and the systemic immune\u2010inflammation index as potential biomarkers of effective treatment and subclinical atherosclerotic cardiovascular disease in patients with psoriasis. J Eur Academy Dermatol Venereol 2023;37. https:\/\/doi.org\/10.1111\/jdv.18860.","DOI":"10.1111\/jdv.18860"},{"key":"9584_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/jvc2.67","volume":"1","author":"L Fern\u00e1ndez Domper","year":"2022","unstructured":"Fern\u00e1ndez Domper L, Paramo JA, Fern\u00e1ndez Alonso L, Martin Hern\u00e1ndez JM, Suarez-Varela MM. Neutrophil-to-lymphocyte ratio as a cardiovascular risk biomarker in psoriasis: a comprehensive review. JEADV Clinical Practice. 2022;1:397\u2013406. https:\/\/doi.org\/10.1002\/jvc2.67.","journal-title":"JEADV Clinical Practice"},{"key":"9584_CR32","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.3390\/jcm12175452","volume":"12","author":"H Albayrak","year":"2023","unstructured":"Albayrak H. Neutrophil-to-lymphocyte ratio, neutrophil-to-monocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index in psoriasis patients: response to treatment with biological drugs. J Clin Med. 2023;12:5452. https:\/\/doi.org\/10.3390\/jcm12175452.","journal-title":"J Clin Med"},{"key":"9584_CR33","doi-asserted-by":"publisher","unstructured":"Najar Nobari N, Shahidi Dadras M, Nasiri S, Abdollahimajd F, Gheisari M. Neutrophil\/platelet to lymphocyte ratio in monitoring of response to TNF\u2010\u03b1 inhibitors in psoriatic patients. Dermatol Ther 2020;33. https:\/\/doi.org\/10.1111\/dth.13457.","DOI":"10.1111\/dth.13457"},{"key":"9584_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s13555-024-01152-w","volume":"14","author":"L Potestio","year":"2024","unstructured":"Potestio L, Tommasino N, Lauletta G, Martora F, Megna M. Psoriasis and molecular target therapies: evidence of efficacy in preventing cardiovascular comorbidities. Dermatol Ther (Heidelb). 2024;14:841\u201352. https:\/\/doi.org\/10.1007\/s13555-024-01152-w.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"9584_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1177\/2047487312444234","volume":"20","author":"E-A Skaug","year":"2013","unstructured":"Skaug E-A, Aspenes ST, Oldervoll L, M\u00f8rkedal B, Vatten L, Wisl\u00f8ff U, Ellingsen \u00d8. Age and gender differences of endothelial function in 4739 healthy adults: the HUNT3 fitness study. Eur J Prev Cardiol. 2013;20:531\u201340. https:\/\/doi.org\/10.1177\/2047487312444234.","journal-title":"Eur J Prev Cardiol"},{"key":"9584_CR36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-024-09584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-024-09584-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-024-09584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:29:28Z","timestamp":1770190168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-024-09584-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9584"],"URL":"https:\/\/doi.org\/10.1007\/s12026-024-09584-4","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"28"}}